This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

F. Bruce Coles, DO
Centers for Disease Control Atlanta New York State Department of Health Albany

Andrew R. Stacy; Dale L. Morse, MD, MS
New York State Department of Health Albany

JAMA. 1989;261(8):1152.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor. —

The Sept 9 issue of THE JOURNAL highlighted the continuing controversy regarding the efficacy of the Haemophilus b polysaccharide vaccine. While the majority of studies cite a vaccine efficacy of 44% to 90%,^1-3 the case-control study from Minnesota raised questions not only regarding efficacy but also about possible negative effects of vaccination.⁴ During 1986, Alexander et al⁵ published population-based data from Jefferson County, Alabama, that showed a significant reduction in the number of cases of invasive Haemophilus influenzae type b (Hib) disease during 1986 among children aged 24 to 48 months, suggesting that the vaccine had lowered the incidence of disease within that age group.

We reviewed age-specific hospitalization information for H influenzae meningitis using federally standardized computer data on all hospital discharges (about 3 million per year) from all general hospitals (N = 295) in New York State (population, 17.76 million) for 1980 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?